Gilead Sciences licences portfolio of HIV antibodies from The Rockefeller University

HIV bNAbs are a class of immunotherapy agents that were originally derived from HIV-infected individuals with a strong anti-HIV immunologic response and were designed to target HIV (Credit: Darwin Laganzon / Pixabay)